An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the future of pharmaceutical advertising, health ...
The FDA has approved Zepbound, a weight-loss medication, as the first drug treatment for moderate to severe obstructive sleep ...
The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating ...
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...
The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the ...
Up to half of obstructive sleep apnea patients taking Zepbound had no symptoms after one year of treatment, averaging 25 ...